• Explore /
  • Poster
  • / Results of the phase 1b study of ABBV-399 (telisotuzumab vedotin; teliso-v) in combination with erlotinib in patients with c-Met+ non-small cell lung cancer by EGFR mutation status.

Results of the phase 1b study of ABBV-399 (telisotuzumab vedotin; teliso-v) in combination with erlotinib in patients with c-Met+ non-small cell lung cancer by EGFR mutation status.

Abstract Poster

Authors

null

D. Ross Camidge

University of Colorado Cancer Center, Aurora, CO

D. Ross Camidge , Fabrice Barlesi , Jonathan Wade Goldman , Daniel Morgensztern , Rebecca Suk Heist , Everett E. Vokes , Alexander I. Spira , ERIC ANGEVIN , Wu-Chou Su , David S. Hong , John H. Strickler , Monica Motwani , Zhaowen Sun , Apurvasena Parikh , Elysa Noon , Jun Wu , Karen Kelly

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2019 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Developmental Therapeutics and Tumor Biology (Nonimmuno)

Track

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Sub Track

Small Molecules

Clinical Trial Registration Number

NCT02099058

Citation

J Clin Oncol 37, 2019 (suppl; abstr 3011)

DOI

10.1200/JCO.2019.37.15_suppl.3011

Abstract #

3011

Poster Bd #

3

Abstract Disclosures

Similar Posters

First Author: Xiuning Le

First Author: Jonathan W. Goldman

First Author: Satoru Miura

First Author: Jonathan W. Riess